Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same?

Vaccine. 2014 Jul 23;32(34):4249-52. doi: 10.1016/j.vaccine.2014.03.024. Epub 2014 Jun 13.


The skin provides the largest immune barrier to infection and is a readily accessible site for vaccination, although intradermal (ID) injection can be challenging. The MicronJet™ microneedle is a novel device that consistently injects antigens very close to the skin's dendritic cells. A dose-sparing ID injection study was conducted in 280 healthy adult volunteers using trivalent virosomal adjuvanted influenza vaccine. ID injection of 3 μg using the MicronJet™ was well tolerated and showed a statistically higher geometric mean fold rise than the same dose ID using a conventional needle (Mantoux technique) for the H1N1 and B strains or a 15 μg intramuscular (IM) injection for the H3N2 strain. Thus, the immune response appears to partially depend on the delivery device and route of injection. The MicronJet™ may allow dose-sparing, yet give a superior response in influenza vaccination and warrants further clinical evaluation.

Keywords: Dose-sparing; Immunogenicity; Influenza vaccination; Intradermal; Mantoux; Microneedle device.

Publication types

  • Clinical Trial, Phase II
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral / blood
  • Dose-Response Relationship, Immunologic
  • Humans
  • Influenza A Virus, H1N1 Subtype
  • Influenza B virus
  • Influenza Vaccines / administration & dosage*
  • Injections, Intradermal / instrumentation*
  • Needles*
  • Vaccines, Virosome / administration & dosage


  • Antibodies, Viral
  • Influenza Vaccines
  • Vaccines, Virosome

Associated data

  • ISRCTN/ISRCTN33950739